Associations of psychiatric disorders with sex chromosome aneuploidies in the Danish iPSYCH2015 dataset: a case-cohort study.
Journal
The lancet. Psychiatry
ISSN: 2215-0374
Titre abrégé: Lancet Psychiatry
Pays: England
ID NLM: 101638123
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
21
07
2022
revised:
15
11
2022
accepted:
29
11
2022
pmc-release:
01
02
2024
entrez:
25
1
2023
pubmed:
26
1
2023
medline:
28
1
2023
Statut:
ppublish
Résumé
Increased prevalence of mental illness has been reported in clinical studies of sex chromosome aneuploidies, but accurate population-based estimates of the prevalence and clinical detection rate of sex chromosome aneuploidies and the associated risks of psychiatric disorders are needed. In this study, we provide such estimates, valid for children and young adults of the contemporary Danish population. We used the iPSYCH2015 case-cohort dataset, which is based on a source population of single-born individuals born in Denmark between May 1, 1981, and Dec 31, 2008. The case sample comprises all individuals from the source population with a diagnosis of any index psychiatric disorder (schizophrenia spectrum disorder, bipolar disorder, major depressive disorder, autism spectrum disorder, or ADHD) by the end of follow-up (Dec 31, 2015), registered in the hospital-based Danish Psychiatric Central Research Register. The cohort consists of individuals randomly selected from the source population, and overlaps with the case sample. Biobanked blood samples for individuals in the case and cohort samples underwent genotyping and quality-control filtering, after which we analysed microarray data to detect sex chromosome aneuploidy karyotypes (45,X, 47,XXX, 47,XXY, and 47,XYY). We estimated the population-valid prevalence of these karyotypes from the cohort sample. Weighted Cox proportional hazards models were used to estimate the risks of each index psychiatric disorder associated with each sex chromosome aneuploidy karyotype, by use of date of first hospitalisation with the index disorder in the respective case group and the cohort as outcome. The clinical detection rate was determined by comparing records of clinical diagnoses of genetic conditions from the Danish National Patient Register with sex chromosome aneuploidy karyotype determined by our study. The assessed sample comprised 119 481 individuals (78 726 in the case sample and 43 326 in the cohort) who had genotyped and quality-control-filtered blood samples, including 64 533 (54%) people of gonadal male sex and 54 948 (46%) of gonadal female sex. Age during follow-up ranged from 0 to 34·7 years (mean 10·9 years [SD 3·5 years]). Information on ethnicity was not available. We identified 387 (0·3%) individuals as carriers of sex chromosome aneuploidies. The overall prevalence of sex chromosome aneuploidies was 1·5 per 1000 individuals. Each sex chromosome aneuploidy karyotype was associated with an increased risk of at least one index psychiatric disorder, with hazard ratios (HRs) of 2·20 (95% CI 1·42-3·39) for 47,XXY; 2·73 (1·25-6·00) for 47,XXX; 3·56 (1·01-12·53) for 45,X; and 4·30 (2·48-7·55) for 47,XYY. All karyotypes were associated with an increased risk of ADHD (HRs ranging from 1·99 [1·24-3·19] to 6·15 [1·63-23·19]), autism spectrum disorder (2·72 [1·72-4·32] to 8·45 [2·49-28·61]), and schizophrenia spectrum disorder (1·80 [1·15-2·80] to 4·60 [1·57-13·51]). Increased risk of major depressive disorder was found for individuals with 47,XXY (1·88 [1·07-3·33]) and 47,XYY (2·65 [1·12-5·90]), and of bipolar disorder for those with 47,XXX (4·32 [1·12-16·62]). The proportion of sex chromosome aneuploidy carriers who had been clinically diagnosed was 93% for 45,X, but lower for 47,XXY (22%), 47,XXX (15%), and 47,XYY (15%). Among carriers, the risk of diagnosis of at least one index psychiatric disorder did not significantly differ between those who had and had not been clinically diagnosed with sex chromosome aneuploidies (p=0·65). Increased risks of psychiatric disorders associated with sex chromosome aneuploidies, combined with low rates of clinical diagnosis of sex chromosome aneuploidies, compromise the adequate provision of necessary health care and counselling to affected individuals and their families, which might be helped by increased application of genetic testing in clinical settings. Lundbeck Foundation and National Institutes of Health.
Sections du résumé
BACKGROUND
Increased prevalence of mental illness has been reported in clinical studies of sex chromosome aneuploidies, but accurate population-based estimates of the prevalence and clinical detection rate of sex chromosome aneuploidies and the associated risks of psychiatric disorders are needed. In this study, we provide such estimates, valid for children and young adults of the contemporary Danish population.
METHODS
We used the iPSYCH2015 case-cohort dataset, which is based on a source population of single-born individuals born in Denmark between May 1, 1981, and Dec 31, 2008. The case sample comprises all individuals from the source population with a diagnosis of any index psychiatric disorder (schizophrenia spectrum disorder, bipolar disorder, major depressive disorder, autism spectrum disorder, or ADHD) by the end of follow-up (Dec 31, 2015), registered in the hospital-based Danish Psychiatric Central Research Register. The cohort consists of individuals randomly selected from the source population, and overlaps with the case sample. Biobanked blood samples for individuals in the case and cohort samples underwent genotyping and quality-control filtering, after which we analysed microarray data to detect sex chromosome aneuploidy karyotypes (45,X, 47,XXX, 47,XXY, and 47,XYY). We estimated the population-valid prevalence of these karyotypes from the cohort sample. Weighted Cox proportional hazards models were used to estimate the risks of each index psychiatric disorder associated with each sex chromosome aneuploidy karyotype, by use of date of first hospitalisation with the index disorder in the respective case group and the cohort as outcome. The clinical detection rate was determined by comparing records of clinical diagnoses of genetic conditions from the Danish National Patient Register with sex chromosome aneuploidy karyotype determined by our study.
FINDINGS
The assessed sample comprised 119 481 individuals (78 726 in the case sample and 43 326 in the cohort) who had genotyped and quality-control-filtered blood samples, including 64 533 (54%) people of gonadal male sex and 54 948 (46%) of gonadal female sex. Age during follow-up ranged from 0 to 34·7 years (mean 10·9 years [SD 3·5 years]). Information on ethnicity was not available. We identified 387 (0·3%) individuals as carriers of sex chromosome aneuploidies. The overall prevalence of sex chromosome aneuploidies was 1·5 per 1000 individuals. Each sex chromosome aneuploidy karyotype was associated with an increased risk of at least one index psychiatric disorder, with hazard ratios (HRs) of 2·20 (95% CI 1·42-3·39) for 47,XXY; 2·73 (1·25-6·00) for 47,XXX; 3·56 (1·01-12·53) for 45,X; and 4·30 (2·48-7·55) for 47,XYY. All karyotypes were associated with an increased risk of ADHD (HRs ranging from 1·99 [1·24-3·19] to 6·15 [1·63-23·19]), autism spectrum disorder (2·72 [1·72-4·32] to 8·45 [2·49-28·61]), and schizophrenia spectrum disorder (1·80 [1·15-2·80] to 4·60 [1·57-13·51]). Increased risk of major depressive disorder was found for individuals with 47,XXY (1·88 [1·07-3·33]) and 47,XYY (2·65 [1·12-5·90]), and of bipolar disorder for those with 47,XXX (4·32 [1·12-16·62]). The proportion of sex chromosome aneuploidy carriers who had been clinically diagnosed was 93% for 45,X, but lower for 47,XXY (22%), 47,XXX (15%), and 47,XYY (15%). Among carriers, the risk of diagnosis of at least one index psychiatric disorder did not significantly differ between those who had and had not been clinically diagnosed with sex chromosome aneuploidies (p=0·65).
INTERPRETATION
Increased risks of psychiatric disorders associated with sex chromosome aneuploidies, combined with low rates of clinical diagnosis of sex chromosome aneuploidies, compromise the adequate provision of necessary health care and counselling to affected individuals and their families, which might be helped by increased application of genetic testing in clinical settings.
FUNDING
Lundbeck Foundation and National Institutes of Health.
Identifiants
pubmed: 36697121
pii: S2215-0366(23)00004-4
doi: 10.1016/S2215-0366(23)00004-4
pmc: PMC9976199
mid: NIHMS1870106
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-138Subventions
Organisme : Medical Research Council
ID : MR/V004905/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W014416/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : R01 MH124789
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH130581
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
Orphanet J Rare Dis. 2010 May 11;5:8
pubmed: 20459843
Mol Biol Cell. 2018 Oct 1;29(20):2458-2469
pubmed: 30091656
Nat Rev Endocrinol. 2019 Oct;15(10):601-614
pubmed: 31213699
J Neurosci. 2017 May 24;37(21):5221-5231
pubmed: 28314818
J Psychiatr Res. 2014 Jan;48(1):128-30
pubmed: 24139812
Curr Opin Endocrinol Diabetes Obes. 2019 Feb;26(1):60-65
pubmed: 30507702
Hum Reprod. 2015 Oct;30(10):2419-26
pubmed: 26251461
Am J Med Genet C Semin Med Genet. 2019 Mar;181(1):126-134
pubmed: 30767374
JAMA Psychiatry. 2022 Jan 1;79(1):59-69
pubmed: 34817560
Scand J Public Health. 2011 Jul;39(7 Suppl):54-7
pubmed: 21775352
Mol Psychiatry. 2018 Jan;23(1):6-14
pubmed: 28924187
Am J Med Genet A. 2010 May;152A(5):1206-12
pubmed: 20425825
PLoS One. 2014 Jun 27;9(6):e101176
pubmed: 24972092
BMC Genet. 2011 Jul 04;12:58
pubmed: 21726430
Pediatrics. 2012 Apr;129(4):769-78
pubmed: 22412026
J Clin Endocrinol Metab. 2006 Apr;91(4):1254-60
pubmed: 16394093
J Neurosci. 2016 Feb 24;36(8):2438-48
pubmed: 26911691
Handb Clin Neurol. 2018;147:355-376
pubmed: 29325624
J Clin Epidemiol. 1999 Dec;52(12):1165-72
pubmed: 10580779
Am J Med Genet A. 2016 Nov;170(11):2870-2881
pubmed: 27644018
Neuropsychopharmacology. 2019 Jan;44(1):9-21
pubmed: 30127341
JAMA Psychiatry. 2022 Aug 1;79(8):818-828
pubmed: 35767289
Curr Opin Psychiatry. 2019 Mar;32(2):79-84
pubmed: 30689602
Cereb Cortex. 2016 Jan;26(1):70-9
pubmed: 25146371
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7398-7403
pubmed: 29946024
Am J Med Genet A. 2021 Dec;185(12):3664-3674
pubmed: 34240550
Genes Brain Behav. 2014 Feb;13(2):127-34
pubmed: 24308542
J Neurodev Disord. 2021 Oct 27;13(1):51
pubmed: 34706642
Endocr Rev. 2018 Aug 1;39(4):389-423
pubmed: 29438472
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
J Pediatr. 2013 Oct;163(4):1085-94
pubmed: 23810129
J Neurodev Disord. 2021 Dec 15;13(1):61
pubmed: 34911436
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5
pubmed: 21775345
Psychol Med. 2001 Apr;31(3):425-30
pubmed: 11305850
Hum Genet. 1991 May;87(1):81-3
pubmed: 2037286
Eur J Hum Genet. 2010 Mar;18(3):265-71
pubmed: 19568271
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Lancet Psychiatry. 2018 Jul;5(7):573-580
pubmed: 29886042
J Neurosci. 2011 May 4;31(18):6654-60
pubmed: 21543594